The US Supreme Court should decline to review a generic drug labeling fight between Amarin and Hikma Pharmaceuticals because the case is “intensely fact-bound” and Hikma’s arguments are “idiosyncratic,” Amarin told justices.
Amarin is pushing ...
↧